News & Media

Kernal Biologics to Present at the 12th International mRNA Health Conference

CAMBRIDGE, Mass., November 11, 2024/ -- Kernal Biologics, Inc. (Kernal Bio) — a development-stage mRNA-technology company developing immunotherapies designed to improve patients' survival rate and quality of life — today announced it is presenting in person at the 12th International mRNA Health Conference in Boston, MA. 

The presentations highlight Kernal Bio’s mRNA LNP platform and in vivo CAR-T program, KR-402.  The company achieved high in vivo delivery efficiency to T-cells with proprietary targeted LNPs. Using these LNPs to deliver CAR mRNA in vivo, Kernal Bio team showed effective B-cell depletion. 

“We are very excited to share our achievements in the mRNA delivery space and showcase KR-402 at the conference. This off-the-shelf mRNA LNP program has the potential to significantly reduce waiting times, cost of goods, and toxicities associated with currently approved CAR-T therapies,” said Kernal Bio Co-founder and Chief Executive Officer Yusuf Erkul, M.D., M.B.A.

On Day 1 of the conference (Tuesday, November 12th), Co-founder and Director of Convergence Science, Dr. Cafer Ozdemir will introduce the Kernal Bio platform and SVP of R&D, Dr. Manfred Kraus, will present data from the company's first in vivo CAR-T program, KR-402. 

Details for the Kernal Bio presentation are as follows: 

Poster Title: T Cell Targeted Peripheral LNPs Drive Highly Effective in situ CAR T Cell Programming 

Presenter: Manfred Kraus, Ph.D.

Time:  November 12, 2024; 5:00 PM

Poster Number: 116

Place: Boston, MA

Presentation & Poster Title:   Design Of mRNA With Cell-Specific Differential Translation 

Presenter: Cafer Ozdemir, Ph.D. 

Time: November 12, 2024; 4:00 PM and 5PM

Poster Number: 109

Place: Boston, MA

About Kernal Biologics, Inc. 

Kernal Bio is pioneering the engineering of human cells inside the body using selective mRNA-LNP technology to fight cancer and autoimmune diseases. By delivering antibody-decorated lipid nanoparticles (LNPs) that precisely target specific cell types, AI-designed mRNAs ensure high specificity and minimize off-target effects within the body. Kernal Bio has demonstrated remarkably high in vivo delivery efficiency (>90%) with our T-cell-targeted mRNA LNPs. Recently, by deploying these for in situ CAR T programming, the company achieved successful in vivo B-cell killing. KR-402 program is being developed for hematological malignancies and autoimmune disorders. The cancer cell-targeting program, KR-335, boasts a 100x therapeutic index, showing high efficacy in solid tumors resistant to conventional immuno-oncology agents. It demonstrated strong tolerability in preclinical models, including mice and non-human primates.

With roots in MIT, Harvard, Merck, and BMS, the management team has led the way with three FDA-approved therapies and 120+ patents. Based in Cambridge, MA, and backed by investors like Hummingbird Ventures, Amgen Ventures, and NASA, Kernal Bio is revolutionizing mRNA therapeutics by harnessing AI to direct precision treatments within the body.

About the mRNA2.0 Platform

Kernal Bio is at the forefront of mRNA therapeutics and synergistically exploits targeted LNP (lipid nanoparticle) delivery and cell-selective translation of its synthetic mRNA, controlling the amount and site of protein produced, without the need for any genetic editing or the risk of genomic integration. Our proprietary best-in-class decorated lipid nanoparticle technology allows us to achieve in situ cell engineering via systemic, targeted, extra-hepatic delivery to specific tissues and cells, such as T cells. The delivery capability, combined with the translation of cell-selective mRNA, eliminates off-target effects. This expertise is enabled by Kernal Bio’s proprietary machine learning (ML) powered platform that discovers RNA sequence motifs from clinical human data with preferential translation based on cell type.